Glaucoma Blockbuster
Increased aqueous outflow from the eye Lowering of intraocular pressure Vision preservation
Therapeutic Clinic Research
Glaucoma is a family of irreversible eye diseases characterized by an increase in intraocular pressure that if left untreated, can permanently damage the optic nerve and lead to blindness. It is estimated that glaucoma will affect 79.6 million people worldwide by the year 2020. The increase in intraocular pressure is due to an increased resistance to the outflow of the “aqueous humor” through the primary drain of the eye, called the “trabecular meshwork”. This results in an increase in intraocular pressure, and if left untreated, can cause a gradual loss of vision, and eventually permanent blindness. Currently, the only rigorously validated treatment for patients with glaucoma is therapeutically lowering intraocular pressure. These therapeutic agents however, simply prevent vision loss, and do not target the primary drainage pathway from the eye, and instead target a secondary outflow site to aqueous humor called the uveoscleral pathway. Researchers at the University of California, Davis have developed a novel therapy to treat glaucoma by targeting the primary drainage pathway from the eye, the “trabecular meshwork”. The novel treatment functions by modulating the stiffness of the trabecular meshwork. This treatment not only stops the progression of glaucoma, but also alleviates intraocular pressure and preserves a patient’s vision.
9206423
Additional Technologies by these Inventors Tech ID/UC Case 24232/2013-196-0 Related Cases 2013-196-0
USA
